[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609849":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":24,"responsibleParty":98,"collaborators":7,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":7,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":7,"enrollmentInfo":109,"targetDuration":7,"studyType":112,"phases":7,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Supernus Pharmaceuticals, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"OTHER","Observational study","Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM)",[14],{"name":15,"affiliation":5,"role":16},"Mindy Grall, PhD ANP-BC","STUDY_CHAIR",[18,22],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","18663980833","mgrall@supernus.com",{"name":23,"role":19,"phone":20,"phoneExt":7,"email":7},"Supernus Supernus",[25,44,57,70,84],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Parkinson's Disease and Movement Disorders Center - Orange County (South)","RECRUITING","Aliso Viejo","California","92656","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-117.72712,33.56504,{"lat":37,"lon":36},[40,42],{"name":41,"role":19,"phone":7,"phoneExt":7,"email":7},"Mindy Bixby, D.O.",{"name":41,"role":43,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":45,"status":27,"city":46,"state":29,"zip":47,"country":31,"countryCode":32,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Parkinson's Disease and Movement Disorders Center - Orange County (North)","Irvine","92618",{"type":34,"coordinates":49},[50,51],-117.82311,33.66946,{"lat":51,"lon":50},[54,56],{"name":55,"role":19,"phone":7,"phoneExt":7,"email":7},"Sandeep Thakkar, D.O.",{"name":55,"role":43,"phone":7,"phoneExt":7,"email":7},{"facility":58,"status":27,"city":59,"state":29,"zip":60,"country":31,"countryCode":32,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Parkinson's Research Centers of America - Palo Alto","Palo Alto","94301",{"type":34,"coordinates":62},[63,64],-122.14302,37.44188,{"lat":64,"lon":63},[67,69],{"name":68,"role":19,"phone":7,"phoneExt":7,"email":7},"Salima Brillman, MD",{"name":68,"role":43,"phone":7,"phoneExt":7,"email":7},{"facility":71,"status":27,"city":72,"state":73,"zip":74,"country":31,"countryCode":32,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Parkinson's Disease & Movement Disorders Center of Boca Raton","Boca Raton","Florida","33486",{"type":34,"coordinates":76},[77,78],-80.0831,26.35869,{"lat":78,"lon":77},[81,83],{"name":82,"role":19,"phone":7,"phoneExt":7,"email":7},"Stuart Isaacson, MD",{"name":82,"role":43,"phone":7,"phoneExt":7,"email":7},{"facility":85,"status":27,"city":86,"state":87,"zip":88,"country":31,"countryCode":32,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Parkinson's Disease and Movement Disorders Center - Long Island","Commack","New York","11725",{"type":34,"coordinates":90},[91,92],-73.29289,40.84288,{"lat":92,"lon":91},[95,97],{"name":96,"role":19,"phone":7,"phoneExt":7,"email":7},"David Kreitzman, M.D.",{"name":96,"role":43,"phone":7,"phoneExt":7,"email":7},{"type":99,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100609849","real-world-patient-experiences-using-continuous-subcutaneous-apomorphine-infusion-onapgotm-in-the-united-states-100609849",false,"NCT07219927","Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:","Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease","Inclusion Criteria:\n\nParticipant has received a prescription for ONAPGO™ according to the standard of care.\n\nParticipant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form.\n\nThe HCP\u002FInvestigator determines the participant is an appropriate study participant.\n\nParticipant is able and willing to provide informed consent (or informed assent form \\[IAF\\], as applicable) and signs the consent form on the Enrollment Day.\n\nExclusion Criteria:\n\nDid not receive a prescription for ONAPGO™.\n\nPrescribed ONAPGO™, but the HCP\u002FInvestigator determines the participant should not participate in this observational study.\n\nConcomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron.\n\nKnown hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).","ALL","18 Years",{"count":110,"type":111},120,"ESTIMATED","OBSERVATIONAL","Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease",[115],"Parkinson Disease",[117],"ONAPGO","2025-10-21",{"date":120,"type":121},"2025-10-22","ACTUAL",{"date":123,"type":121},"2025-03-31",{"date":125,"type":111},"2027-08-01",{"name":5,"class":6},5]